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The main object of this research work is to develop and studying the stability analysis of orodispersible tablet of piroxicam. Five formulations 
of orodispersible tablets of piroxicam (F1-F4) were prepared using two different superdisintegrants namely crospovidone and sodium 
starch glycolate with two concentrations and a control F5 (without superdisintegrant) by direct term stability studies for the formulations 
showed no significant changes in disintegration compression method. The precompression and post compression study of piroxicam and 
excipient were carried out. The short time, drug content and percentage of drug released when stored at 4°C±2°C, 27°C ±2°C, and 45°C±2°C 
for 15 days.
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INTRODUCTION
Orodispersible tablet system can be defined as a tablet that 
disintegrates and dissolves rapidly in saliva within few seconds without 
need of drinking water or chewing. In spite of tremendous development 
in drug delivery technology, the oral route remains perfect route for 
administration of therapeutic reagents because of the low cost of therapy, 
ease of administration, accurate dose, self-medication, pain avoidance, 
leading to high level of patient compliance. The benefits, in terms of 
patient compliance, rapid onset of action, increased bioavailability, and 
good stability not require water for oral administration, have a pleasing 
mouth feel, have an acceptable taste masking property make these 
tablets popular as a dosage form of choice [1,2]. Piroxicam is a potent 
anti-inflammatory drug. It is used in the treatment of osteoarthritis, 
rheumatoid arthritis, ankylosing spondylitis, and acute gout disease. 
It has prolonged the half-life of about 45 hrs. Piroxicam has pKa 
about 6.3. It is poorly water soluble drug and when administered 
orally; it may cause bioavailability problems due to its poor solubility 
and dissolution rates in biological fluids. Hence, the present work was 
aimed at increasing the rate of dissolution of piroxicam thus providing 
a faster rate of absorption by adding potential superdisintegrants such 
as crospovidone (CP) and sodium starch glycolate (SSG) in different 
concentrations. To mask the bitter taste of piroxicam, saccharin sodium 
was used as the sweetening agent. Four formulations of orodispersible 
tablets of Piroxicam using two superdisintegrants namely CP and SSG 
and a control formulation (without superdisintegrant) were prepared 
by direct compression method.
MATERIALS
The drug piroxicam was a generous gift sample from Concept 
Pharmaceuticals Pvt. Ltd., Aurangabad. SSG, CP, mannitol, magnesium 
stearate, saccharine sodium, microcrystalline cellulose were supplied 
S.D. Fine Chemicals (Mumbai). Other reagents and organic solvents 
used were of analytical grade.
METHODS
Orodispersible tablets of piroxicam were prepared by direct 
compression method by using superdisintegrant SSG, CP together with 
a binding agent like microcrystalline cellulose. Magnesium stearate was 
used as lubricants.
Preparation of mouth dissolving tablet
Piroxicam orodispersible tablets were prepared by direct compression 
method according to the formula given in Table 1. A total number of four 
formulations (F1-F4) of piroxicam orodispersible tablets were prepared 
using two superdisintegrants namely CP and SSG with two different 
concentrations [1-3]. A control tablet was also prepared without any 
superdisintegrant (F5). All the ingredients were passed through mesh 
No. 60 separately and collected. The drug, mannitol, and microcrystalline 
cellulose were mixed uniformly with gentle trituration using mortar and 
pestle to get a uniform mixture. The required quantity of superdisintegrant 
and saccharin sodium were taken for each specified formulation and 
mixed with the above mixture and compressed on a 8 station tablet 
machine (Jaguar JM-D) equipped with round 8-mm punches [4,5].
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Table 1: Formulation of piroxicam orodispersible tablets by design expert
S. No. Composition F1 (mg) F2 (mg) F3 (mg) F4 (mg) F5 (mg)
1 Piroxicam 20 20 20 20 20
2 SSG 15 5 5 15 -
3 CP 5 15 5 5 -
4 Microcrystalline cellulose 100 100 110 90 120
5 Mannitol 51 51 51 51 51
6 Saccharin sodium 7 7 7 7 7
7 Magnesium stearate 2 2 2 2 2
8 Menthol q.s q.s q.s q.s q.s
Total 200 200 200 200 200
CP: Crospovidone, SSG: Sodium starch glycolate
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Drug excipient interaction study
Fourier transform infrared spectroscopy (FTIR)
It was used to study the interactions between the drug and the 
excipients. The KBR disk method was used for the preparation of 
sample and spectra were recorded over the wave number 4000 to 
400/cm in a BRUKER FTIR spectrophotometer. IR spectral studies 
of Pure Piroxicam, superdisintegrant and piroxicam containing the 
highest proportion of individual superdisintegrant were carried out. If 
there was no change in peaks of the mixture when compared to the pure 
drug, it indicates the absence of interactions.
Evaluation of powder blend [6]
The blend were characterized by their micromeritics properties, such 
as, bulk density, tapped density, Carr’s compressibility index, Hausner 
ratio, and flow property.
Bulk density
The bulk density was obtained by dividing the mass of powder by 
the bulk volume in cm3. The sample of about 10 cm3 of powder was 
carefully introduced into a 25 ml graduated cylinder. The cylinder was 
dropped at 2-second intervals onto a hard wood surface three times 
from a height of 1 inch. The bulk density of each formulation was then 
obtained by dividing the weight of the sample in grams by the final 
volume in cm3 of the sample contained in the cylinder. It was calculated 
using equation given below:
Df = M/Vp
Where, Df=Bulk density,
M=Weight of samples in grams,
Vp=Final volumes of granules in cm3.
Tapped density
 The tapped density was obtained by dividing the mass of powder by 
the tapped volume in cm3. The sample of about 10 cm3 of powder is 
carefully introduced into a 25 ml graduated cylinder. The cylinder was 
dropped at 2-second intervals onto a hard wood surface 100 times 
from a height of 1 inch. The tapped density of each formulation was 
then obtained by dividing the weight of the sample in grams by the final 
tapped volume in cm3 of the sample contained in the cylinder. It was 
calculated using equation given below:
Do=M/Vp
Where, Do=Bulk density,
M=Weight of samples in grams,
Vp=Final tapped volumes of granules in cm3.
Carr’s index
The percentage compressibility of microspheres was calculated 









Where, Df=Bulk density, Do=Tapped density
Hausner ratio
The Hausner ratio of a microsphere was calculated according to 
equation given below:
Hausner ratio= Do/Df
Table 3: Evaluation of powder blend
Batch code Angle of response Bulk density (g/cm3) Tapped density (g/cm3) Compressibility index (%) Hausner’s ratio*
F1 30°.11±0.031 0.327±0.075 0.357±0.012 14.95±0.021 0.896±0.045
F2 31°.11±0.022 0.314±0.045 0.392±0.025 11.30±0.036 0.874±0.032
F3 30°.99±0.039 0.320±0.041 0.363±0.063 14.41±0.065 0.893±0.047
F4 30°.58±0.042 0.314±0.056 0.373±0.051 14.67±0.028 0.869±0.063
F5 32°.23±0.037 0.325±0.049 0.360±0.089 14.54±0.087 0.880±0.098
*Each sample was analyzed in triplicate (n=3)
Fig. 2: Infrared spectra of drug + excipient
% Compressibility Flow ability
5-15 Excellent
12-16 Good




Fig. 1: Infrared spectra of drug
Table 2: Relationship between % compressibility and flow 
ability
Fig. 3: Percentage drug release profile of piroxicam formulation
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The angle of repose of powder blend was determined by the funnel 
method. The accurately weighed powder blend was taken in the funnel. 
The height of the funnel was adjusted in such a way that the tip of the 
funnel just touches the heap of the powder blend. The powder blends 
were allowed to flow through the funnel freely onto the surface. The 
diameter of the powder cone was measured, and angle of repose was 
calculated using the following equation,
θ= tan−1 (h/r)
Where, “h” and “r” are the height and radius of the cone.
Evaluation of tablets [6-9]
Weight variation
20 tablets were randomly selected and individually weighed. The 
average weight of tablets was calculated. Then the individual weight 
was compared with that of average weight.
Hardness
The tablets to be tested are held between a fixed and a moving jaw of 
hardness test apparatus (Monsanto) and reading of the indicator is 
adjusted to zero. The screw knob was moved forward until the tablet 
breaks and the force required to break the tablet was noted.
Friability
Friability test was performed using Roche friabilator. 10 tablets were 
weighed and placed in the friabilator, which was then operated for 25 
revolutions per minute. After 100 revolutions, the tablets were dusted 
and reweighed. The percentage friability was determined using the 
formula:
Percentage friability






In vitro disintegration time
The test was carried out in a disintegration apparatus using distilled 
water (at 37°C±0.50°C) as disintegration medium. A tablet was placed 
in each of six tubes of the apparatus, and one disc was added to each 
tube. The time taken for complete disintegration of the tablet with no 
mass remaining in the apparatus was measured in seconds.
Wetting time
Wetting time is closely related to the inner structure of the tablets 
and hydrophilicity of the excipients. The wetting time of the tablets 
was measured using a simple procedure. Five circular tissue papers of 
10-cm diameter were placed in a Petri dish with a 10-cm diameter. 10 
ml of water containing methylene blue, a water-soluble dye was taken 
in the Petri dish. A tablet was carefully placed on the surface of tissue 
paper. The time required for water to reach the upper surface of the 
tablets was noted as the wetting time.
In vitro drug release [10,11]
In vitro dissolution studies for all the formulated tablets of piroxicam 
was carried out using an electrolab paddle method at 50 rpm in 900 ml 
of pH 6.8 buffer solution as a dissolution medium. The dissolution 
medium was maintained at 37°C±5°C. 10 ml of sample was withdrawn 
at 10 minutes intervals of time. 10 ml of buffer solution (pH 6.8) was 
replaced to maintain the constant volume throughout the experiment. 
The samples were suitably diluted, and the percentage of drug released 
from each formulation was measured at 333 nm using a ultraviolet-
visible spectrophotometer.
Stability studies [1]
The stability test was carried out to evaluate the stability of piroxicam 
in formulated tablets after storing at different temperatures for 15 days. 
The prepared tablets were kept at three different temperatures such as 
4°C±2°C, 27°C±2°C, and 45°C±2°C for 15 days. Every 5 days interval, the 
tablets were evaluated for the hardness, disintegration time and in vitro 
drug release studies.
RESULTS AND DISCUSSION
Orodispersible tablets of piroxicam were prepared by direct 
compression method using CP and SSG as superdisintegrants. A total 
of four formulations (F1-F4) and a control formulation F5 (Without 
Superdisintegrant) were designed. The values of precompression 
parameters evaluated were found to be within the prescribed limits and 
indicated good free flowing property (Table 3). IR spectroscopy was 
used as means of studying drug-excipients compatibility and confirmed 
by comparing undisturbed structure of IR spectra of Piroxicam, which 
indicated no drug-excipients interaction.
CONCLUSION
The results of experimental studies of piroxicam orodispersible 
tablets proved that the powder blend of piroxicam showed good flow 















F1 199.7±0.9 4.18±0.58 3.2±0.123 0.75±0.314 31±0.35 20±0.52
F2 198.1±1.2 4.20±0.61 2.7±0.152 0.55±0.235 34±0.39 13±0.23
F3 200.8±1.6 4.15±0.39 3.2±0.163 0.84±0.386 39±0.37 23±0.36
F4 200.3±1.8 4.11±0.62 3.1±0.175 0.44±0.863 42±0.51 21±0.34
F5 200.7±1.1 4.17±0.75 3.5±0.169 0.54±0.172 139±0.45 12±0.58
*Each sample was analyzed in triplicate (n=3)
The data obtained of post-compression parameters such as hardness,
 thickness, friability, weight variation, amount of drug 
content, disintegration time and water absorption ratio are shown 
in Table 4. Tablets obtained were of uniform weight (due to uniform 
die fill) with acceptable variation as per Indian Pharmacopoeia (IP) 
specifications, i.e., below 7.5%. The low standard deviation values 
indicating efficient mixing of drug, disintegrants, and excipients. 
The hardness of the tablets was found to be 3.2±0.123-3.1±0.175 
kg/cm2. The thickness of tablets was found to be 4.11±0.62-4.20±0.61
 mm. The result revealed that the tablets of all the formulations 
showed uniform thickness. In all the formulations, the friability 
values were <1% and meet the IP limits. The results of in vitro 
disintegration time of all the formulations were found to be within the 
prescribed limits and satisfied the criteria of fast dissolving tablets. 
The values were found to be in the range of 31±0.35 to 42±0.51 
seconds. The percentage of the drug released for formulation 
F1 showed better drug release of (98.64±0.64) than F4 
(93.79±0.59) and control F5 (91.45±0.57) at the end of 60 minutes 
(Table 5 and Fig. 2). Further formulation F1, F4, and F5 were subjected 
to stability studies for the period of 15-day at 40°C±20°C, 
27°C±2°C, and 45°C±20°C and were analyzed after specific time 
period of 5-day interval. No significant changes were seen in 
disintegration time and in vitro drug release after 15 days.
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properties, tablet evaluation tests are within the acceptable limits, IR 
spectral analysis proved that there was no drug excipient and stability 
studies revealed that all the formulations were found to be stable after 
storing at 4°C±2°C, 27°C±2°C, and 45°C±2°C for 15 days. The drawbacks 
of the conventional dosage forms of Piroxicam can be minimized by 
piroxicam orodispersible tablets. The formulations prepared with 
superdisintegrant showed a rapid drug release than control (without 
superdisintegrant) formulation. Thus, the results of the above study 
clearly indicated that piroxicam may be formulated as orodispersible 
tablets using two superdisintegrants CP and SSG by direct compression 
method.
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